MRNA Moderna, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1682852 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY10.5%
TTM EPS YoY12.7%
Revenue 3-yr CAGR-34.8%
Net income 3-yr CAGR—
Margins
Gross margin28.0%
Operating margin-116.0%
Net margin-110.5%
FCF margin-78.0%
EBITDA margin-106.6%
Returns
ROE-34.5%
ROA-21.8%
ROIC (approx.)-33.4%
Asset turnover0.20x
Leverage & solvency
Liabilities / assets49.2%
Debt / equity0.00x
Current ratio3.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue7.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.31B | $145.00M | $389.00M | $678.00M | $1.02B | $142.00M | $108.00M | $966.00M |
| Cost of revenue | $318.00M | $93.00M | $955.00M | $452.00M | $207.00M | $119.00M | $90.00M | $739.00M |
| Gross profit | $995.00M | $52.00M | -$566.00M | $226.00M | $809.00M | $23.00M | $18.00M | $227.00M |
| R&D expense | $583.00M | $651.00M | $649.00M | $775.00M | $801.00M | $700.00M | $856.00M | $1.12B |
| SG&A expense | $282.00M | $216.00M | $173.00M | $308.00M | $268.00M | $230.00M | $212.00M | $351.00M |
| Operating income | $130.00M | -$815.00M | -$1.39B | -$857.00M | -$260.00M | -$907.00M | -$1.05B | -$1.25B |
| Pretax income | $171.00M | -$767.00M | -$1.33B | -$799.00M | -$187.00M | -$818.00M | -$964.00M | -$1.18B |
| Income tax | $9.00M | $15.00M | $9.00M | $27.00M | $13.00M | $7.00M | $7.00M | -$64.00M |
| Net income | $162.00M | -$782.00M | -$1.34B | -$826.00M | -$200.00M | -$825.00M | -$971.00M | -$1.12B |
| EBITDA | $191.00M | -$759.00M | -$1.33B | -$791.00M | -$209.00M | -$851.00M | -$1.01B | -$1.19B |
| EPS (basic) | 0.40 | -1.97 | -3.40 | — | -0.51 | -2.13 | -2.52 | — |
| EPS (diluted) | 0.38 | -1.97 | -3.40 | — | -0.51 | -2.13 | -2.52 | — |
| Weighted avg. shares (diluted) | 430.00M | 398.00M | 395.00M | — | 390.00M | 388.00M | 386.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.20B | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B |
| Short-term investments | $3.98B | $3.42B | $3.30B | $3.20B | $3.37B | $3.85B | $4.35B | $5.10B |
| Receivables | $1.37B | $17.00M | $71.00M | $184.00M | $1.05B | $36.00M | $78.00M | $358.00M |
| Inventory | $313.00M | $280.00M | $146.00M | $153.00M | $332.00M | $240.00M | $128.00M | $117.00M |
| Current assets | $7.34B | $5.82B | $5.77B | $6.54B | $6.60B | $6.17B | $6.77B | $8.10B |
| PP&E, net | $2.04B | $2.06B | $2.09B | $2.13B | $2.13B | $2.17B | $2.21B | $2.20B |
| Goodwill | $52.00M | $52.00M | $52.00M | $52.00M | $52.00M | $52.00M | $52.00M | $52.00M |
| Intangibles | $102.00M | $109.00M | $116.00M | $45.00M | $47.00M | $48.00M | $49.00M | $40.00M |
| Total assets | $13.47B | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B |
| Current liabilities | $2.03B | $2.53B | $2.40B | $1.99B | $1.68B | $1.57B | $1.60B | $2.21B |
| Long-term debt | — | $591.00M | $590.00M | $590.00M | — | — | — | $0 |
| Total debt | — | $591.00M | $590.00M | $590.00M | — | — | — | $0 |
| Total liabilities | $6.63B | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B |
| Shareholders' equity | $6.84B | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B |
| Net debt | — | -$1.13B | -$1.32B | -$2.00B | — | — | — | -$1.93B |
| Shares outstanding | 404.00M | 399.00M | 397.00M | 394.00M | 391.00M | 389.00M | 387.00M | 386.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.56B | -$526.00M | -$630.00M | $930.00M | -$847.00M | -$919.00M | -$1.04B | $825.00M |
| Capital expenditure | $47.00M | $37.00M | $62.00M | $39.00M | $33.00M | $3.00M | $117.00M | $522.00M |
| Free cash flow | -$1.61B | -$563.00M | -$692.00M | $891.00M | -$880.00M | -$922.00M | -$1.15B | $303.00M |
| Investing cash flow | -$1.72B | $329.00M | -$76.00M | -$48.00M | $700.00M | $564.00M | $730.00M | -$539.00M |
| Financing cash flow | $2.75B | $14.00M | $17.00M | $581.00M | -$1.00M | $9.00M | $4.00M | -$3.00M |
| Depreciation & amortization | $61.00M | $56.00M | $56.00M | $66.00M | $51.00M | $56.00M | $38.00M | $59.00M |
| Stock-based compensation | $127.00M | $120.00M | $104.00M | $113.00M | $125.00M | $130.00M | $115.00M | $104.00M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.